ROCKVILLE, Md.--(BUSINESS WIRE)--Prolias, a biotechnology company working to discover and develop novel therapeutic proteins and antibodies for treatment of disease, today announced a strategic acquisition of technology from the University of Maryland Biotechnology Institute (UMBI). The new technology will extend Prolias’ discovery platform, FIoNATM, by providing a platform for the creation of fully human, recombinant antibodies from diverse, endogenous antibody sources.
